Search Within

Michael Andrew Postow

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (48)
  2. Meeting Abstract (34)
  3. Research Letter (2)
Groups
  1. Department of Medicine (84)
  2. Epidemiology and Biostatistics (84)
  3. Melanoma Disease Management Team (84)
  4. Melanoma and Immunotherapeutics Service (84)
  5. Solid Tumor Oncology Division (84)
  6. Biostatistics Service (78)

More Groups

People
  1. Katherine Panageas (64)
  2. Jedd Wolchok (48)
  3. Alexander Shoushtari (40)
  4. Margaret Callahan (37)
  5. Paul Chapman (34)
  6. Parisa Momtaz (28)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (8)
  5. 2021 (8)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (32)
  2. Annals of Surgical Oncology (5)
  3. Journal for ImmunoTherapy of Cancer (5)
  4. The Oncologist (5)
  5. Clinical Cancer Research (4)
  6. JAMA Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (33)
  2. American Association for Cancer Research (6)
  3. Oxford University Press (6)
  4. Biomed Central Ltd (5)
  5. Nature Publishing Group (5)
  6. Springer (5)

More Publishers

Results (84)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma
    Meeting Abstract

    Postow, M. A.; Chasalow, S. D.; Yuan, J.; Kuk, D.; Panageas, K. S.; Cheng, M.; Shahabi, V.; Berman, D. M.; Wolchok, J. D.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Ipilimumab for patients with advanced mucosal melanoma
    Journal Article

    Postow, M. A.; Luke, J. J.; Bluth, M. J.; Ramaiya, N.; Panageas, K. S.; Lawrence, D. P.; Ibrahim, N.; Flaherty, K. T.; Sullivan, R. J.; Ott, P. A.; more...
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Meeting Abstract

    Postow, M. A.; Yuan, J.; Panageas, K.; Bogatch, K.; Callahan, M.; Cheng, M.; Schroeder, S. E. A.; Kendle, R. F.; Harding, J. J.; Dickson, M. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
    Meeting Abstract

    Kitano, S.; Postow, M. A.; Cortez, C.; Rasalan, T.; Gallardo, H. F.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Lesokhin, A. M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save